公开(公告)号：EP2981258B1

公开(公告)日：2020-08-12

申请号：EP14778339.3

申请日：2014-04-03

申请人： ScPharmaceuticals Inc.

发明人： MICHAELS, Scott, A. ,  MUNTENDAM, Pieter ,  LARSEN, Glenn, R.

IPC分类号： A61K31/341 ,  A61K9/00 ,  A61K47/02 ,  A61K47/18 ,  A61K9/08 ,  A61K31/635 ,  A61P9/12 ,  A61P9/04

公开(公告)号：EP2981258A1

公开(公告)日：2016-02-10

申请号：EP14778339.3

申请日：2014-04-03

申请人： ScPharmaceuticals Inc.

发明人： MICHAELS, Scott, A. ,  MUNTENDAM, Pieter ,  LARSEN, Glenn, R.

IPC分类号： A61K31/341

摘要： The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

公开(公告)号：EP2981258B8

公开(公告)日：2020-11-11

申请号：EP14778339.3

申请日：2014-04-03

申请人： scPharmaceuticals Inc.

发明人： MICHAELS, Scott, A. ,  MUNTENDAM, Pieter ,  LARSEN, Glenn, R.

IPC分类号： A61K31/341 ,  A61K9/00 ,  A61K47/02 ,  A61K47/18 ,  A61K9/08 ,  A61K31/635 ,  A61P9/12 ,  A61P9/04